Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Boehringer Ingelheim

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Litigation Details for Apple Inc. v. WI-LAN Inc. (S.D. Cal. 2014)

See Plans and Pricing

« Back to Dashboard

Apple Inc. v. WI-LAN Inc. (S.D. Cal. 2014)

Docket   Start Trial Date Filed 2014-09-19
Court District Court, S.D. California Date Terminated
Cause 28:2201dj Declaratory Judgment Assigned To Dana Makoto Sabraw
Jury Demand Defendant Referred To Barbara Lynn Major
Patents 5,010,010
Attorneys Allison H. Goddard; Amy H. Walters; Andrew Stein; Ashlee Nicole Lin; Ashley Nicole Moore; Brett E Cooper; Christopher J. Gaspar; Christopher Paul McNett; Courtland Lewis Reichman; Dat T. Nguyen; Deborah Ruth Rosenthal; Dirk D. Thomas; Drew Bennett Hollander; Elisa Lee; Erin Paige Gibson; Gayle Klein; Jacob Anderson; Jennifer Lynne Miremadi; John Allcock; John Yang; Jonathan R. Yim; Kevin R. Schubert; Lawrence M. Hadley; Mark Christopher Scarsi; Michael K Sheen; Miguel Jesus Ruiz; Mike McKool , Jr.; Paul Alan Lesko; Peter P. Maggiore; Robert A. Auchter; Robert A. Cote; Robert Buergi; Robert Chen Williams; Sarah S. Burns; Sean C Cunningham; Seth R. Hasenour; Steven J. Pollinger; Tiffany Carol Miller; Warren Henry Lipschitz
Firms DLA Piper LLP; DLA Piper LLP (US); DLA Piper US; McKool Smith; McKool Smith Hennigan PC; McKool Smith P.C.; Michael K Sheen; Milbank Tweed Hadley and McCloy LLP; Milbank, Tweed, Hadley & McCloy LLP; Patterson Law Group, APC; Robert Buergi; Simmons Hanly Conroy
Link to Docket External link to docket
Biologic Drugs cited in Apple Inc. v. WI-LAN Inc.
The biologic drug covered by the patent cited in this case is   Start Trial .

Details for Apple Inc. v. WI-LAN Inc. (S.D. Cal. 2014)

Date Filed Document No. Description Snippet Link To Document
2018-07-31 478 702 (ECF No. 328 at 13-23, 23-35; ECF No. 384 at 5-10, 10-15; ECF No. 415 17 at 8-12; ECF No. 422 at 1…standard-essential patents based 28 merely on numbers. If a patent holder owns ten out of a hundred patents essential…comparability analysis for licenses to patents other than the Patents-in-Suit. See M2M 25 Sols. LLC v. …challenges being faced by 18 patent holders in enforcing their patents because this would threaten to… evidence of royalty stacking in this case; (C) Patent Counting, performing 8 arbitrary arithmetic External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.